Moleculin Plans Annamycin Pancreatic Cancer Trial in 2027

• Moleculin Biotech announced preclinical results showing Annamycin combined with PD-1 checkpoint blockade extended survival in pancreatic cancer mice versus either treatment alone.
• A second independent experiment confirmed the survival benefit, supporting potential development of the combination in pancreatic cancer.
• The findings will be presented today at the Marie Skłodowska-Curie Symposium on Cancer Research and Care in Tampa, Florida.
• An investigator-initiated pancreatic cancer trial is planned for 2027.
• The MIRACLE trial in acute myeloid leukemia remains the immediate priority, with a data readout expected in the first quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611101445PRIMZONEFULLFEED9874334) on November 10, 2026, and is solely responsible for the information contained therein.